Deerfield Management’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Deerfield Management’s Portfolio FPRX Stock Details FPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q1	–	Sell	-450,728	Closed	-$9.88M	–	130
2017 Q4	$9.88M	Buy	+450,728	New	+$14.5M	0.39%	69
2017 Q2	–	Sell	-138,000	Closed	-$4.99M	–	104
2017 Q1	$4.99M	Hold	138,000	–	–	0.19%	86
2016 Q4	$6.92M	Sell	138,000 -173,000	-56%	-$9.09M	0.28%	70
2016 Q3	$16.3M	Sell	311,000 -137,000	-31%	-$6.54M	0.76%	40
2016 Q2	$18.5M	Sell	448,000 -232,000	-34%	-$10.1M	0.73%	47
2016 Q1	$27.6M	Hold	680,000	–	–	1.18%	31
2015 Q4	$28.2M	Buy	+680,000	New	+$22.8M	1.14%	36

Other funds holding FPRX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Deerfield Management's FPRX Position: Q1 2018 in Review

Deerfield Management sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2018, closing a stake of 450,728 shares — an estimated $9.88M sold.

Deerfield Management first reported a position in FPRX in Q4 2015 and held it in 7 quarters. The position peaked at $28.2M in Q4 2015. 128 funds tracked by Wall St. Rank hold FPRX as of Q1 2018.

Deerfield Management reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2018 after selling out during the quarter.
Deerfield Management sold 450,728 Five Prime Therapeutics, Inc. shares in Q1 2018, an estimated $9.88M.
Deerfield Management first reported a position in Five Prime Therapeutics, Inc. in Q4 2015 and held it in 7 quarters.
Deerfield Management's Five Prime Therapeutics, Inc. position peaked at $28.2M in Q4 2015.
128 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2018.

Based on Deerfield Management's 13F filing for Q1 2018, filed 15 May 2018.